bioRxivCancer Biology
Lymph Node Morphology in Stage II Colorectal Cancer
A. Greenwood, J. Keating, D. Kenwright, A. Shekouh, A. Dalzell, E. Dennett, K. Danielson
Abstract
BackgroundColorectal cancer is one of the leading causes of cancer-associated morbidity and mortality worldwide. The local anti-tumour immune response is particularly important for patients with stage II where the tumour-draining lymph nodes have not yet succumbed to tumour spread. The lymph nodes allow for the expansion and release of B cell compartments such as primary follicles and germinal centres. A variation in this anti-tumour immune response may influence the observed clinical heterogeneity in stage II patients. AimThe aim of this study was to explore tumour-draining lymph node histomorphological changes and tumour pathological risk factors including the immunomodulatory microRNA-21 (miR-21) in a small cohort of stage II CRC. MethodsA total of 23 stage II colorectal cancer patients were included. Tumour and normal mucosa samples were analysed for miR-21 expression levels and B-cell compartments were quantified from Haematoxylin and Eosin slides of lymph nodes. These measures were compared to clinicopathological risk factors such as perforation, bowel obstruction, T4 stage and high-grade. ResultsWe observed greater follicle density in patients with a lower tumour T stage and higher germinal centre density in patients with higher pre-operative carcinoembryonic antigen levels. Trends were also detected between tumours with deficiency in mismatch repair proteins, lymphatic invasion and both the density and size of B-cell compartments. Lastly, elevated tumour miR-21 was associated with decreased follicle and germinal centre size. ConclusionVariation in B-cell compartments of tumour-draining lymph nodes is associated with clinicopathological risk factors in stage II CRC patients. What does this paper add to the literature?This study demonstrates the variability of tumour draining lymph node morphological features in stage II CRC patients. This provides new scope for biomarker discovery in stage II CRC patients which is a research priority for this patient group.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular subtyping improves prognostication of Stage 2 colorectal cancer
R. V. Purcell, S. Schmeier, … F. A. Frizelle·bioRxiv·Jun 20, 2019
- Identification of histological features to predict MUC2 expression in colon cancer tissues
P. K. Periyakoil, M. Clarke, D. Sahoo·bioRxiv·Mar 21, 2019
- Whole-Slide ECM Imaging Reveals Dense Fibrous Matrix as a High-Risk Factor for Recurrence in Stage II Colon Cancer
Cor J. Ravensbergen, V.S. Colaco, … Wilma E. Mesker·bioRxiv·Nov 14, 2024
- MUC2 Expression Modulates Immune Infiltration in Colorectal Cancer
Christophe Michel Raynaud, Ayesha Jabeen, … W. R. L. Hendrickx·Frontiers in ImmunologyPeer-reviewed·Jan 24, 2025
- Circulating microRNA-762 upregulates colorectal cancer might through Wnt-1/b-catenin signaling
P.-S. Lai, W.-M. Chang, … C.-Y. Chen·bioRxiv·Apr 22, 2020
- Immunophenotypic changes in peripheral blood of colorectal cancer patients: a potential diagnostic marker for CD4+ monocytes
Khin Aye Thin, Andrew Cross, … Steven W. Edwards·ImmunobiologyPeer-reviewed·Jul 1, 2026